A new approach to drug therapy in non-alcoholic steatohepatitis (NASH)

Journal of International Medical Research

Volumn 31, Issue 6, 2003, Pages 537-551

  Feher J ^a   Lengyel, G ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Metadoxine; Non alcoholic steatohepatitis; Pathogenesis; Pathology; Therapy

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; BETAINE; BLEOMYCIN; CORTICOSTEROID; CYTOCHROME P450 2E1; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METADOXINE; METHOTREXATE; PHOSPHATIDYLCHOLINE; SELENIUM; SILYMARIN; TAMOXIFEN; TETRACYCLINE; TRIACYLGLYCEROL; UBIQUINONE; URSODEOXYCHOLIC ACID; VALPROIC ACID;

ALCOHOL CONSUMPTION; ALCOHOLIC FATTY LIVER; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ECHOGRAPHY; ENTERITIS; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; ILEUM BYPASS; INBORN ERROR OF METABOLISM; KUPFFER CELL; LIFESTYLE; LIPID PEROXIDATION; LIPID STORAGE; LIVER CELL; LIVER FAILURE; LIVER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL DEFICIENCY; OBESITY; OXIDATIVE STRESS; PARENTERAL NUTRITION; PREGNANCY; PROTEIN DEFICIENCY; RISK FACTOR; WEIGHT REDUCTION;

EID: 0348149059     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000303100610     Document Type: Article

References (48)

1. Ludwig J, Viggiano TR, McGill DB, Ott BJ: Nonalcoholic steatohepatitis. Mayo Clinic experiences with hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438.
2. Leevy CM: Fatty liver. A study of 270 patients with biopsy proven fatty liver and review of the literature. Medicine 1962; 41: 249-276.
3. Fehér J, Romics L, Jakab L, Fehér E, Szilvási I, Papp G: Serum lipids and lipoproteins in chronic liver disease. Acta Med Acad Sci Hung 1976; 33: 217-223.
4. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ: Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669.
5. James OF, Day CP: Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998; 29: 495-501.
6. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
7. Parola M, Robino G: Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001; 35: 297-306.
8. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C: Hepatic cytochrome P450 2E1 is increased in patients with non-alcoholic steatohepatitis. Hepatology 1998; 27: 128-133.
9. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR: CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-1075.
10. Rockey DC, Boyles, JK, Gabbiani G, Friedman SL: Rat hepatic lipocytes express smooth muscle octin upon activation in vivo and in culture. J Submicrosc Cytol Pathol 1992; 24: 193-203.
11. Sakaida I, Nagatomi A, Hironaka K, Uchida K, Okita K: Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy. Am J Gastroenterol 1999; 94: 489-496.
12. Reeves HL, Burt AD, Wood S, Day CP: Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol 1996; 25: 677-683.
13. Clouston AD, Jonsson JR, Purdie DM, Macdonald GA, Pandeya N, Shorthouse C, et al: Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 2001; 34: 314-320.
14. Bonkovsky HL, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, et al: Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421-429.
15. Lebensztejn D, Sobaniec-Lotowska M, Kaczmarski M, Bialokoz I, Mikoluc B, Sulik M: Steatohepatitis with regard to morphological - mainly ultrastructural - picture of oligobio-punctate of the liver. Case Rep Clin Pract Rev 2001; 2: 203-207.
16. Scheen AJ: Diabetes mellitus, glitazones and hepatotoxicity. International Diabetes Monitor 2001; 13(4). Available at: http://www.medforum.nl/idm/leading_article6.htm (last accessed 28 April 2003).
17. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-1109.
18. Dray X, Tainturier MH, De La Lande P, Marty O, Mallet L. Cirrhosis with non alcoholic steatohepatitis: role of tamoxifen (in French, English abstract). Gastroenterol Clin Biol 2000; 24: 1122-1123.
19. Murata Y, Ogawa Y, Saibara T, Nishioka A, Fujiwara Y, Fukumoto M, et at: Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 2000; 7: 1299-1304.
20. Grieco A, Alfei B, Di Rocco P, Miele L, Biolcati G, Griso D, et al Non-alcoholic steatohepatitis induced by carbamazepine and variegate porphyria. Eur J Gastroenterol Hepatol 2001; 13: 973-975.
21. Sanyal AJ: Nonalcoholic steatohepatitis. Clin Perspect Gastroenterol 2000; S: 129-139.
22. Riley CA: Liver disease in the pregnant patient. Am J Gastroenterol 1999; 94: 1728-1732.
23. Wilcken B, Leung KC, Hammond J, Kamath R, Leonard JV: Pregnancy and fetal long chain 3-hydroxyacyl coenzyme A dehydrogenase deficiency. Lancet 1993; 341: 407-408.
24. Heinonen S, Eloranta ML, Heiskanen J, Punnonen K, Helisalmi S, Mannermaa A, et al: Maternal susceptibility locus for obstetric cholestasis maps to chromosome region 2p13 in Finnish patients. Scand J Gastroenterol 2001; 36: 766-770.
25. Manton ND, Lipsett J, Moore DJ, Davidson GP, Bourne AJ, Couper RT: Non-alcoholic steatohepatitis in children and adolescents. Med J Aust 2000; 173: 476-479.
26. Angulo P, Lindor KD: Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001; 21: 81-88.
27. Diehl AM, Goodman Z, Ishak KG: Alcohol-like liver disease in nonalcoholics. A clinical and histological comparison with alcohol-induced liver injury. Gastroenterol 1988; 95: 1056-1062.
28. Lee RG: Nonalcoholic steatohepatitis. A study of 49 patients. Hum Pathol 1989; 20: 594-598.
29. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al: Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-107.
30. Vajro P, Fontanella A, Perna C, Orso G, Tedeso M, De Vicenzo A: Persistent hyperamino-transferasemia resolving after weight reduction in obese children. J Pediatr 1994; 125: 239-241.
31. Kanders BS, Blackburn GL: Very low calorie diets for the treatment of obesity. In: Obesity, Pathophysiology, Psychology and Treatment (Blackburn GL, Kanders BS, eds). New York: Chapman and Hall, 1994; pp197-215.
32. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM: Metformin reverses fatty liver disease in obese, leptin deficient mice. Nat Med 2000; 6: 998-1003.
33. Teli MR, James OF, Burt AD, Bennett MK, Day CP: The natural history of nonalcoholic fatty liver: a follow up study. Hepatology 1995; 22: 1714-1719.
34. Day CP, James OF: Steatohepatitis: a tale of two 'hits'? Gastroenterol 1998; 114: 842-845.
35. Fehér J, Csomós G, Vereckei A: Free Radical Reactions in Medicine. Heidelberg: Springer Verlag, 1987; pp107-122.
36. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A: Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 1667-1672.
37. Gulbahar O, Karasu ZA, Ersoz G: Treatment of nonalcoholic steatohepatitis with N-acetylcysteine (abstract). Gastroenterol 2000; 118: 1444A.
38. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al: Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-1467.
39. Fehér J, Sulyok S, Várnai K, Pollák Z, Toncsev H, Sréter L, et al: The effect of a new synthetic dihydroquinoline type antioxidant in experimental atherosclerosis. Lipid Research 1984; 4: 20-26.
40. Fehér J, Bar-Pollák Z, Sréter L, Fehér E, Toncsev H: Biochemical markers in carbon-tetrachloride- and galactosamine-induced acute liver injuries: the effects on dihydroquinoline-type antioxidants. Br J Exp Pathol 1982; 63: 394-400.
41. Fehér J, Lengyel G, Blazovics A: Oxidative stress in liver and biliary tract diseases. Scand J Gastroenterol 1988; 228 (Suppl): 38-48.
42. Annoni G, Contu L, Tronci MA, Caputo A, Arosio B: Pyridoxol L,2-pyrolidon-5 carboxylate prevents active fibroplasia in CC14 treated rats. Pharmacol Res 1992; 25: 87-93.
43. Calabrese V, Bombaci G, Colderone A, Rizza V: Effects of metadoxine on cellular free fatty acid levels in ethanol treated rats. Int J Tiss Reac 1993; 15: 235-243.
44. Hogymási K, Blázovics A, Kocsis I, Feher J: Effects of metadoxine - a liver protecting agent on short-term extrahepatic cholestasis. Current Topics in Biophysics 2000; 24: 69-73.
45. Gutierrez-Ruiz MC, Bucio L, Correa A, Souza V, Hernandez E, Gomez-Quiroz LE, et al: Metadoxine prevents damage produced by ethanol and acetaldehyde in hepatocyte and hepatic stellate cells in culture. Pharmacol Res 2001; 44: 431-436.
46. Caballeria J, Pares A, Brú C, Mercader J, Garcia Plaza A, Caballeria L, et al: Metadoxine accelerates fatty liver recovery in alcoholic patients: results of randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver. J Hepatol 1998; 28: 54-60.
47. Pinto HC, Baptista A, Camillo ME, Valente A, Saragoca A, de Moura MC: Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996; 41: 172-179.
48. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM: Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999; 282: 1659-1664.